1. Home
  2. BEAM vs LFST Comparison

BEAM vs LFST Comparison

Compare BEAM & LFST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

HOLD

Current Price

$27.72

Market Cap

2.7B

Sector

Health Care

ML Signal

HOLD

Logo LifeStance Health Group Inc.

LFST

LifeStance Health Group Inc.

HOLD

Current Price

$7.04

Market Cap

2.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BEAM
LFST
Founded
2017
2015
Country
United States
United States
Employees
N/A
8040
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Medical/Nursing Services
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.7B
2.7B
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
BEAM
LFST
Price
$27.72
$7.04
Analyst Decision
Buy
Strong Buy
Analyst Count
12
6
Target Price
$50.75
$9.83
AVG Volume (30 Days)
2.0M
1.4M
Earning Date
05-06-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
82.31
N/A
EPS
N/A
N/A
Revenue
$24,000.00
$1,424,285,000.00
Revenue This Year
N/A
$17.18
Revenue Next Year
$33.77
$14.02
P/E Ratio
N/A
N/A
Revenue Growth
33.33
13.85
52 Week Low
$15.52
$3.74
52 Week High
$36.44
$8.09

Technical Indicators

Market Signals
Indicator
BEAM
LFST
Relative Strength Index (RSI) 48.95 63.92
Support Level $25.89 $6.75
Resistance Level $29.06 $7.33
Average True Range (ATR) 1.67 0.17
MACD 0.18 0.07
Stochastic Oscillator 47.35 93.08

Price Performance

Historical Comparison
BEAM
LFST

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

About LFST LifeStance Health Group Inc.

LifeStance Health Group Inc is a mental healthcare company that operates as a provider of outpatient mental health services, spanning psychiatric evaluations and treatment, psychological and neuropsychological testing, and individual, family, and group therapy. It treats a broad range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder, using evidence-based approaches to ensure effective treatment. The group has a single operating and reportable segment of mental health services.

Share on Social Networks: